Aspire Biopharma Holdings (ASBP) Enterprise Value (2022 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Enterprise Value of -$1.8 million for Q1 2026, down 35.66% year-over-year from -$2.8 million in Q1 2025, and down 35.66% quarter-over-quarter from -$1.3 million in Q1 2025.
Aspire Biopharma Holdings (ASBP) Enterprise Value (2022 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Enterprise Value for 5 consecutive years, with -$1.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 35.66% year-over-year to -$1.8 million; the TTM figure through Mar 2026 stood at -$1.8 million (down 35.66% YoY), while the FY2024 annual figure was -$3633.0, up 67.49% from the prior year.
- Enterprise Value eased to -$1.8 million in Q1 2026 per ASBP's latest filing, from -$1.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$3633.0 in Q4 2024 and bottomed at -$1.8 million in Q1 2026.
- Historically, Enterprise Value has averaged -$484578.2 across 5 years, with a median of -$406205.5 in 2022.
- Annual changes were most pronounced in 2023 — Enterprise Value surged 97.75% — and 2025, when it sank 2747.6%.
- Aspire Biopharma Holdings' Enterprise Value stood at -$497259.0 in 2022, then soared by 97.75% to -$11174.0 in 2023, then jumped by 67.49% to -$3633.0 in 2024, then slumped by 36964.22% to -$1.3 million in 2025, then sank by 35.66% to -$1.8 million in 2026.
- Business Quant data shows ASBP's Enterprise Value at -$1.8 million in Q1 2026, -$1.3 million in Q1 2025, and -$3633.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 2.12 Bn |
| 10 | Aspire Biopharma Holdings | 8.34 Mn | -3.83 Mn | -30,086.00 | -12.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.17 Mn |
| Mar 31, 2026 | -1.83 Mn |
| Mar 31, 2025 | -1.35 Mn |
| Dec 31, 2024 | -3,633.00 |
| Sep 30, 2024 | -16,541.00 |
| Jun 30, 2024 | -19,604.00 |
| Mar 31, 2024 | -47,287.00 |
| Dec 31, 2023 | -11,174.00 |
| Mar 31, 2023 | -315,152.00 |
| Dec 31, 2022 | -497,259.00 |
| Sep 30, 2022 | -533,129.00 |
| Jun 30, 2022 | -579,751.00 |
| Mar 31, 2022 | -618,122.00 |